IDWeek 2013

Daptomycin Demonstrates Potential in MRSA Bloodstream Infections

By October 06, 2013

Daptomycin may be a feasible treatment option for patients with Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection when vancomycin MICs are 1.5-2.0 μg/mL.

Lopinavir/Ritonavir Prophylaxis Well Tolerated in High-Risk Neonates

By October 06, 2013

HIV Prophylaxis with twice-daily lopinavir/ritonavir was well tolerated in high-risk neonates without adverse drug events, as reported at IDWeek 2013.

Girls with HIV without Viral Load Suppression Have Lowest Responses to qHPV

By October 06, 2013

Girls 9-13 years with HIV who received the quadrivalent human papillomavirus vaccine (qHPV) had significantly lower peak geometric mean titers (GMT) vs. same-aged girls without HIV infection, a study presented at IDWeek 2013 has found.

High Completion Rate with 3-Month Isoniazid + Rifapentine Regimen for Latent Tuberculosis

By October 06, 2013

The completion rate of a 12-dose, 3-month isoniazid/rifapentine (3HP) regimen in this study (83.7%) is comparable to its completion rate in Study 26 (82.1%), and is significantly higher than the average 55.0% completion rate for the 9-month isoniazid regimen that was reported in Arkansas for the past 5 years, according to results presented at IDWeek 2013.

Pyrazinamide Therapy Safe for Elderly with Pulmonary Tuberculosis

By October 06, 2013

Pyrazinamide is safe in elderly patients >80 years old not experiencing malnourishment, low-grade ADL, and previously elevated liver enzymes, as presented by Ryutaro Tanizaki, MD, from the National Center for Global Health and Medicine, Tokyo, Japan at IDWeek 2013.

Fidaxomicin Highly Effective in Cancer Patients with <i>C. difficile</i> Infection

By October 06, 2013

Fidaxomicin was highly effective in patients with cancer treated for the first episode of C. difficile infection (CDI) after failure of standard therapy and in patients with recurrent CDI, results of a study presented at IDWeek 2013.

Similar Pathogen Frequency in Hospital- and Community- Associated Abdominal Infections

By October 06, 2013

Distribution patterns of species was similar in hospital-associated (HA) and community-associated (CA) intra-abdominal infections (IAI), according to study results presented at IDWeek 2013.

Crofelemer Well Tolerated in HIV Patients with Non-Infectious Diarrhea

By October 06, 2013

In HIV-seropositive patients on antiretroviral therapy (ART) with non-infectious diarrhea, crofelemer 125mg twice daily was well tolerated with a low incidence of adverse events and no clinical deterioration of immune status, study investigators reported at IDWeek 2013.

Daclatasvir + Sofosbuvir Effective in Prior Telaprevir or Boceprevir Failures

By October 06, 2013

Once-daily oral combination of daclatasvir (DCV) + sofosbuvir (SOF) with or without ribavirin (RBV) achieved sustained virologic response (SVR) in chronic HCV GT1 infected patients with prior telaprevir (TVR) or boceprevir (BOC) + peginterferon/ribavirin treatment failures.

Antifungal Prophylaxis Decreases Induction Mortality Rates in Pediatric AML

By October 06, 2013

Antifungal prophylaxis is associated with significant reduction in induction mortality rates in pediatric patients with acute myeloid leukemia (AML) and reduced supportive care resources utilization.

HBV Vaccine Response Status Not Associated with cART CD4 Gains at 1-Year

By October 06, 2013

Hepatitis B virus (HBV) vaccine response status was not associated with post-combination antiretroviral therapy (cART) CD4 gains at 1-year among those with virologic suppression, a study concluded at IDWeek 2013.

Antibiotic + Probiotic Combo Reduces Rate of Recurrent UTI in Peds

By October 05, 2013

Combination fluoroquinolone plus probiotic for the eradication of Quiescent Intracellular Reservoirs (QIRs) resulted in a decrease of recurrent urinary tract infections (UTI) in pediatric patients.

Similar Efficacy Seen With Cefazolin and Oxacillin for High-Burden MSSA Infections

By October 05, 2013

In methicillin-sensitive Staphylococcus aureus (MSSA) bloodstream infections (BSI), cefazolin may have similar rates of clinical cure as oxacillin, including treatment of high-burden infections, according to IDWeek 2013.

Novel Formulations of Meningococcal Vaccines Elicit Similar Seroresponse Rates

By October 05, 2013

Investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y elicited similar responses in adolescents to those anticipated from the constituent ACWY and B vaccines, a study presented at IDWeek 2013 has found.

5-Nitroimidazoles More Effective in Treatment of Giardiasis

By October 05, 2013

A systematic review of 30 randomized controlled trials (RCTs) showed the 5-nitroimidazoles demonstrated efficacy in the treatment of giardiasis, a study concluded at IDWeek 2013.

SOLO 1: Oritavancin and Vancomycin Achieve Similar Lesion Reduction

By October 05, 2013

Similar achievement of >20% reduction of lesion size was noted in patients treated with oritavancin and vancomycin for acute bacterial skin and skin structure infections at Hours 48 and 72, a study at IDWeek 2013 has found.

Lactam + Aminoglycoside Combo Gives Lowest Dual-Resistance

By October 05, 2013

Resistance patterns for antibiotics used against Gram-negative bacteria over the past 12 years are linked to initial double-coverage of suspected Gram-negative species, a study reported at IDWeek 2013.

Patients with HIV Infection, Early Syphilis Benefit from Single Dose of Benzathine Penicillin

By October 05, 2013

A single dose of benzathine penicillin G is sufficient to treat patients with HIV infection and early syphilis, a study presented at IDWeek 2013 has found.

Earlier Stability Achieved with Linezolid vs. Vancomycin in VAP Due to MRSA

By October 05, 2013

Patients with ventilator-associated pneumonia (VAP) due to methicillin-resistant Staphylococcus aureus (MRSA) achieved an earlier time to clinical stability when treated with linezolid vs. vancomycin, results of the IMPACT-HAP study reported at IDWeek 2013.

High Mortality Rates in ICU Patients Receiving >24 Hours of Inappropriate Antibiotics

By October 05, 2013

ICU patients who receive more than 24 hours of inappropriate antibiotics have a higher mortality rate; this risk factor is not observed with inappropriate antibiotic use within the first 24 hours, a study concluded at IDWeek 2013.

Ceftolozane/Tazobactam Provides Greater Coverage than Beta-Lactams for <i>P. auroginosa</i>

By October 05, 2013

Ceftolozane/tazobactam exhibited potent antimicrobial activity when tested against Pseudomonas aeruginosa isolates from US medical centers, including multidrug-resistant strains, a study reported at IDWeek 2013.

Influenza Infection, Vaccination During Pregnancy Have No Effect on Common Maternal Outcomes

By October 05, 2013

In a cohort of pregnant women, no associations were found between the 2010-2011 seasonal influenza infection or vaccination and four common maternal outcomes—gestational hypertension, preeclampsia/eclampsia, gestational diabetes, and chorioamnionitis—a prospective study concluded at IDWeek 2013.

Low Risk of Treatment Failure When Using Penicillins vs Third-Generation Cephalosporins for CAP

By October 05, 2013

Penicillins may be used with low risk of treatment failure for patients with community-acquired pneumonia (CAP), a case-control study reported at IDWeek 2013 has found.

Sofosbuvir + Peginterferon alfa-2a/Ribavirin Effective in Patients with HCV/HIV Co-Infection

By October 05, 2013

Treatment with sofosbuvir + peginterferon alfa-2a/ribavirin for 12 weeks in treatment-naïve, HIV/HCV co-infected patients led to a highly effective sustained virologic response rate, results of a study presented at IDWeek 2013.

Single-Tablet Regimens RPV/FTC/TDF, EFV/FTC/TDF Non-inferior in ART-Naïve Patients

By October 04, 2013

Week 48 "snapshot analysis" finds two single tablet regimens non-inferior for virologic suppression in treatment-naïve patients with HIV-1 infection, the STaR study reported at IDWeek 2013.

Single-Tablet HIV Regimen Maintains Virologic Suppression, Improves Fasting Lipids

By October 04, 2013

Patients with HIV-1 treated with rilpivirine/emtricitabine/tenofovir DF once-daily single-tablet regimen maintained virologic suppression at 48 weeks regardless of initiation time.

Similar Rates of Recurrent SSTIs With Clindamycin and TMP-SMX Therapy

By October 04, 2013

Researchers did not observe a difference in recurrent infections when treated with either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) in patients with uncomplicated skin and soft tissue infections (uSSTIs), according to results presented at IDWeek 2013.

Higher Discontinuation Rate with Nafcillin vs. Cefazolin in MSSA

By October 04, 2013

Significantly high rates of premature treatment discontinuation was observed in patients treated with either nafcillin or cefazolin, with high rates of drug-related adverse events (DRAE) occurring with nafcillin treatment, as presented at IDWeek 2013.

Combination HIV Drugs Safe and Effective in Treatment-Naïve Black Patients

By October 04, 2013

Elvitegravir/cobicistat/emtricitabine/tenofovir DF was well-tolerated and safe compared with efavirenz/emtricitabine/tenofovir DF in treatment-naïve Black patients with HIV infection, a study presented at IDWeek 2013 has found.

Daptomycin Therapy Not Influenced by Renal Function in Patients With MRSA Bacteremia

By October 04, 2013

Renal impairment of any kind had no significant impact on the efficacy of daptomycin vs. vancomycin in the treatment of MRSA bacteremia, a study presented at IDWeek 2013 has concluded.